Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Well Pharmaceutical Group Co (SHSE:603351) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nanjing Well Pharmaceutical Group Co EBITDA Margin % Related Terms
Nanjing Well Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Well Pharmaceutical Group Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Well Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Well Pharmaceutical Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanjing Well Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nanjing Well Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Well Pharmaceutical Group Co (SHSE:603351) has a EBITDA Margin % of 13.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Well Pharmaceutical Group Co and its competitors. This is 37% below median its historical median of 21.16. Over the past decade, Nanjing Well Pharmaceutical Group Co's EBITDA Margin % has ranged from 13.81 to 23.67. According to the industry distribution chart, Nanjing Well Pharmaceutical Group Co ranks #436 out of 958 companies in the Drug Manufacturers industry, placing it in the top 45.5%.
Is Nanjing Well Pharmaceutical Group Co's EBITDA Margin % too high?
Nanjing Well Pharmaceutical Group Co's current EBITDA Margin % of 13.41% is 37% below median its 10-year median of 21.16. Over the past 10 years, this metric has ranged from a low of 13.81 to a high of 23.67. The Drug Manufacturers industry median EBITDA Margin % is 11.93. Nanjing Well Pharmaceutical Group Co's value of 13.41% is 12.4% above this industry median. Based on the distribution chart, Nanjing Well Pharmaceutical Group Co ranks #436 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Nanjing Well Pharmaceutical Group Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Well Pharmaceutical Group Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nanjing Well Pharmaceutical Group Co ranks #436 out of 958 companies for EBITDA Margin %. This puts Nanjing Well Pharmaceutical Group Co in the upper half of its industry. The industry median EBITDA Margin % is 11.93. Nanjing Well Pharmaceutical Group Co's value of 13.41% is 12.4% above this benchmark. Historically, Nanjing Well Pharmaceutical Group Co's own EBITDA Margin % has ranged from 13.81 to 23.67 over the past decade. While the company's 10-year median is 21.16 vs. the industry median of 11.93, Nanjing Well Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.93, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Well Pharmaceutical Group Co's current EBITDA Margin % of 13.41% is 12.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nanjing Well Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Well Pharmaceutical Group Co's current EBITDA Margin % is 13.41%, which is 37% below median its own 10-year median of 21.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Well Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Well Pharmaceutical Group Co (SHSE:603351) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.01, compared to a current price of ¥26.93 — trading 3.9% below its estimated fair value. The current EBITDA Margin % is 13.41%, which is 37% below median its 10-year median of 21.16 and 12.4% above the Drug Manufacturers industry median of 11.93. Nanjing Well Pharmaceutical Group Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nanjing Well Pharmaceutical Group Co (SHSE:603351), the current EBITDA Margin % is 13.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Well Pharmaceutical Group Co (SHSE:603351) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Well Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥26.93 is trading 3.9% below its estimated GF Value™ of ¥28.01.
GuruFocus considers Nanjing Well Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603351:
EBITDA Margin %: 13.41% (37% below median its 10-year median of 21.16)
GF Value™: ¥28.01 vs. price of ¥26.93 (3.9% below fair value)
Industry Position: 12.4% above the Drug Manufacturers median (#436 of 958)
No single metric tells the full story. See the SHSE:603351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Well Pharmaceutical Group Co Ltd is engaged in research and development, production and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil and other products. The company uses a variety of pharmaceutical dosage forms such as injection, oral administration and external use to guarantee the molding, effectiveness, stability and safety of pharmaceutical dosage forms.
81GF Score
Get the complete analysis for SHSE:603351
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603351 has been successfully added to your 
